Conditions: Neoplasms, Uterine Cervix Metastatic Cervical Cancer
Keywords: pazopanib ErB1/ErB2 lapatinib persistent VEGF recurrent metastatic cervical cancer advanced FIGO Stage IVB
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 228
Healthy volunteers: no

Brief summary:
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer

Detailed description:
A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with International Federation of Gynecology (FIGO) Stage IVB or Recurrent or Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen for Advanced/Recurrent Disease

Arms:
arm 1: Pazopanib plus lapatinib arm 2: Lapatinib arm 3: Pazopanib

Interventions: intervention 1: pazopanib (GW786034) intervention 2: lapatinib (GW572016)
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: